By the crucial relationship of LRP1 expression with the infiltration of macrophages and CAFs abundance, our manuscript indicated that LRP1 was an immune suppressive factor in the tumor microenvironment of BLCA, further influencing patients’ responsiveness to ICBs therapy. The gene discussed is LRP1; the disease is bladder transitional cell carcinoma.